WO2005016937A1 - A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE - Google Patents

A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE Download PDF

Info

Publication number
WO2005016937A1
WO2005016937A1 PCT/CN2004/000792 CN2004000792W WO2005016937A1 WO 2005016937 A1 WO2005016937 A1 WO 2005016937A1 CN 2004000792 W CN2004000792 W CN 2004000792W WO 2005016937 A1 WO2005016937 A1 WO 2005016937A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
formula
chloro
ethyl
compound
Prior art date
Application number
PCT/CN2004/000792
Other languages
French (fr)
Chinese (zh)
Inventor
Weiming Fan
Hanghui Weng
Jianming Ding
Bingjun Ren
Original Assignee
Zhejiang Zhenyuan Phamaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Zhenyuan Phamaceutical Co., Ltd. filed Critical Zhejiang Zhenyuan Phamaceutical Co., Ltd.
Publication of WO2005016937A1 publication Critical patent/WO2005016937A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Definitions

  • the present invention relates to a method for synthesizing a key intermediate of the non-steroidal anti-inflammatory analgesic "lornoxicam", and more particularly to 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, Synthetic method of 3-e) -1, 2-thiazine-1, 1-dioxide-3-carboxylic acid ester.
  • U.S. Patent No. 4,180,662 discloses a method for preparing 5-chloro-3- (N-methoxycarbonylmethylene-N-methyl) -aminosulfonylthiophene 2-carboxylic acid
  • the ester (Formula 2) was used as a raw material, and the cyclization reaction was performed by heating in a methanol solution containing sodium methoxide. After the reaction was completed, 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3 -e) -l, 2-thiazine-1,1-dioxide-3-carboxylic acid methyl ester (formula 1).
  • the object of the present invention is to provide a 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1, 2-thiazine-1, 1-diol with high yield.
  • Method of oxide-3-carboxylic acid ester Method of oxide-3-carboxylic acid ester.
  • the inventors believe that the low yield of the existing production method is directly related to the too strong alkalinity of the sodium cyclizing reagent sodium methoxide.
  • the basic cyclization reagent made by the simple metal with a slightly lower metal activity than the metal sodium will give better results.
  • an organic magnesium reagent is used instead of an organic sodium reagent, and the cyclization reaction is performed in an alcohol solvent, thereby greatly improving the reaction yield.
  • the present invention provides a method for preparing 6-chloro-4-hydroxy-2-methyl-2H-thieno (2,3-e) -1,2-thiazine-1 having the general formula 3 , 1-dioxide-3-carboxylic acid ester method,
  • is ⁇ - ⁇ ⁇ group
  • the method includes:
  • 1 3 and ⁇ 4 respectively represent a c r c 4 fluorenyl group; (b) isolating the compound of formula 3 from the reaction mixture.
  • the use of magnesium alkoxide as the basic cyclization can reduce the occurrence of side reactions, thereby greatly improving the yield of the compound of formula 3, and further reducing the production cost of the compound of formula 3.
  • the present invention provides a method for synthesizing a compound of formula 3, which comprises the steps of: (a) using a magnesium alkoxide as a basic cyclizing agent, and cyclizing a corresponding compound of formula 4 in an organic solvent to form a compound of formula 3, ( b) The compound of formula 3 is then isolated.
  • C fluorenyl selected from C fluorenyl.
  • it is selected from the group consisting of methyl, ethyl, propyl and butyl; more preferably, ⁇ is methyl and ethyl.
  • the compound of formula 4 has the general formula:
  • R 3 and! ⁇ are selected from C CJ amidino, respectively.
  • R 3 and! ⁇ are respectively selected from methyl, ethyl, propyl and butyl; more preferably, and are methyl and ethyl, respectively.
  • Magnesium ethoxide can be expressed by Formula 5:
  • R 2 is selected from a fluorenyl group of C 6 .
  • R 2 is selected from methyl, ethyl, propyl, butyl, pentyl and Hexyl; more preferably, R 2 is selected from methyl, ethyl, propyl and butyl; most preferably, R 2 is methyl, ethyl isopropyl and n-propyl.
  • the preparation of the magnesium alkoxide can be carried out by reacting and synthesizing elemental magnesium with excess C r C 6 alcohol at a temperature higher than room temperature.
  • the temperature is preferably the reflux temperature of the alcohol.
  • the alcohol may be a monohydric alcohol or -Ce comprising ( ⁇ - (: Solvent 6 monohydric alcohol; preferably, the solvent is preferably alone ( "C 6 monohydric alcohol; and more preferably, the solvent is More preferred are methanol, ethanol, isopropanol, and n-propanol alone.
  • the solvent of the present invention may also be a mixed solution mainly containing (1% alcohol: 6 alcohol (mainly refers to a content greater than 70%, preferably greater than 80%), such as a tetrahydrofuran mixed solution mainly containing 1% alcohol ( 6 alcohol).
  • the cyclization reaction step (a) of the present invention is performed in a solvent.
  • the solvent used is preferably an alcohol (especially a monohydric alcohol) or a mixed solvent thereof.
  • the temperature range of the cyclization reaction is not particularly limited, and is usually between 40 ° F and the reflux temperature of the selected solvent, especially the reflux temperature of the C 6 alcohol can reach 157 ° C.
  • the reaction temperature ranges from 40 to 125 ° C, more preferably from 55 to 120 ° C, and most preferably from 60 to 10 ° C.
  • the boiling points of common solvents are as follows (normal pressure):
  • step (b) the compound of formula 3 can be isolated by methods conventional in the art (such as those described in US 4, 180, 662).
  • a preferred separation method is extraction with dichloromethane / 2N HC1 mixed solution, and drying and concentration to obtain a crude product of the compound of formula 3.
  • the product can be obtained after washing with organic solution (such as methanol), filtering, and drying.
  • organic solution such as methanol
  • Example 1 The following describes the present invention in detail with reference to the examples. These examples are for illustrative purposes only and do not limit the scope of the present invention.
  • Example 1
  • the molar yield of Compound 1 in the prior art is only 24%, while the molar yield of Compound 1 in the present invention can reach up to 77.2%, which is more than 3 times higher than the prior art, thereby greatly reducing The production cost has a very large application prospect.

Abstract

This invention provided a synthetic method for 6-chloro-4-hydroxy-2-methyl-2H-thieno (2,3-e)-1,2-thiazine-1, 1-dioxide-3-carboxylate of formula 3. The method included following steps: (a) cyclizing the compound of formula 4 by alkoxy magnesium which used as an alkaline cyclization agent, in the organic solvent and at 40°C-157°C reaction temperature, and (b) the compound of formula 3 was separated from the reaction mixture. The method in this invention could enhanced the yield of production remarkably.

Description

嗪 -1,1-二氧化物 -3-羧酸酯  Azine-1,1-dioxide-3-carboxylic acid ester
的合成方法  Synthetic method
技术领域  Technical field
本发明涉及非甾体消炎镇痛药 "氯诺昔康" (lornoxicam)的关键中间体的合 成方法, 更具体涉及 6-氯 -4-羟基 -2-甲基 -2H-噻吩并 (2, 3-e)-l , 2-噻嗪 -1, 1-二氧 化物 -3-羧酸酯的合成方法。 技术背景  The present invention relates to a method for synthesizing a key intermediate of the non-steroidal anti-inflammatory analgesic "lornoxicam", and more particularly to 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, Synthetic method of 3-e) -1, 2-thiazine-1, 1-dioxide-3-carboxylic acid ester. technical background
目前, 国内外己上市以 "氯诺昔康" 为活性成分的片剂与冻干制剂用以治疗 类风湿性关节炎、 骨关节炎及手术后的各种疼痛。 其突出的镇痛效果可与临床上 常用的吗啡、 曲马多相媲美。  At present, tablets and lyophilized preparations with "Lornoxicam" as the active ingredient have been marketed at home and abroad for the treatment of rheumatoid arthritis, osteoarthritis and various pains after surgery. Its outstanding analgesic effect is comparable to morphine and tramadol commonly used in clinical practice.
国内外对此产品的临床研究也在随着其市场前景的逐渐看好而有所增长。 然 而, 由于 "氯诺昔康" 的关键中间体的化学合成难度较大, 国内外公开发表的相 关合成文献也是凤毛麟角。  The clinical research on this product at home and abroad has also increased with the gradual optimism of its market prospect. However, due to the difficulty in chemical synthesis of key intermediates of "Lornoxicam", relevant synthetic literature published at home and abroad is also rare.
美国专利 US 4, 180, 662公开了一种制法, 该方法以 5-氯- 3- (N-甲氧羰基亚甲 基 -N-甲基) -氨基磺酰噻吩- 2-羧酸甲酯(式 2)为原料, 在含有甲醇钠的甲醇溶液 中加热进行环合反应,待反应结束后,分离得到 6-氯 -4-羟基 -2-甲基 -2H-噻吩并 (2 , 3-e)-l, 2-噻嗪 -1, 1-二氧化物 -3-羧酸甲酯 (式 1 ) 。 然而, 在以上合成过程中, 副反应的发生量很大, 反应溶液颜色很深, 导致最后收率很低, 摩尔收率仅为约 24%。
Figure imgf000003_0001
因此, 本领域迫切需要开发新的收率高的制备 6-氯 -4-羟基 -2-甲基 -2H-噻吩并 (2, 3-e)-l, 2-噻嗪 -1, 1-二氧化物 -3-羧酸酯的方法。 发明内容
U.S. Patent No. 4,180,662 discloses a method for preparing 5-chloro-3- (N-methoxycarbonylmethylene-N-methyl) -aminosulfonylthiophene 2-carboxylic acid The ester (Formula 2) was used as a raw material, and the cyclization reaction was performed by heating in a methanol solution containing sodium methoxide. After the reaction was completed, 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3 -e) -l, 2-thiazine-1,1-dioxide-3-carboxylic acid methyl ester (formula 1). However, in the above synthesis process, a large amount of side reactions occurred, and the color of the reaction solution was very dark, resulting in a low final yield, and the molar yield was only about 24%.
Figure imgf000003_0001
Therefore, there is an urgent need in the art to develop new preparations of 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1, 2-thiazine-1, 1- Dioxide-3-carboxylic acid ester method. Summary of the invention
本发明的目的是提供一种高收率地制备 6-氯 -4-羟基 -2-甲基 -2H-噻吩并 (2, 3-e)-l , 2-噻嗪 -1, 1-二氧化物 -3-羧酸酯的方法。  The object of the present invention is to provide a 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1, 2-thiazine-1, 1-diol with high yield. Method of oxide-3-carboxylic acid ester.
本发明人经过深入而广泛的研究, 认为现有生产方法收率低与碱性环合试剂甲醇 钠的碱性太强有直接关系。根据金属活性强弱的顺序关系, 用金属活性比金属钠稍差 的单质金属代替金属钠, 制成的碱性环合试剂会得到较好的结果。通过降低环合反应 中使用的环合试剂的碱性, 例如以有机镁试剂代替有机钠试剂, 在醇类溶剂中进行环 合反应, 可以大大提高反应的收率。  After intensive and extensive research, the inventors believe that the low yield of the existing production method is directly related to the too strong alkalinity of the sodium cyclizing reagent sodium methoxide. According to the order relationship of the metal activity, the basic cyclization reagent made by the simple metal with a slightly lower metal activity than the metal sodium will give better results. By reducing the basicity of the cyclization reagent used in the cyclization reaction, for example, an organic magnesium reagent is used instead of an organic sodium reagent, and the cyclization reaction is performed in an alcohol solvent, thereby greatly improving the reaction yield.
基于上述原因, 本发明提供了一种制备通式为式 3的 6-氯 -4-羟基 -2-甲基- 2H-噻吩并(2, 3- e) -l, 2-噻嗪- 1, 1-二氧化物 -3-羧酸酯的方法,  Based on the above reasons, the present invention provides a method for preparing 6-chloro-4-hydroxy-2-methyl-2H-thieno (2,3-e) -1,2-thiazine-1 having the general formula 3 , 1-dioxide-3-carboxylic acid ester method,
Figure imgf000004_0001
Figure imgf000004_0001
3  3
式中, ^是^-^垸基;  In the formula, ^ is ^-^ 垸 group;
该方法包括:  The method includes:
(a)以式 5的垸氧基镁作为碱性环合剂, 在有机溶剂和 40°C -157°C反应温度  (a) Using methoxy magnesium of formula 5 as a basic cyclizing agent, in an organic solvent and a reaction temperature of 40 ° C -157 ° C
(R20)2Mg 式中, !^是^-^烷基; (R 2 0) 2 Mg In the formula,! ^ Is ^-^ alkyl;
使式 4的化合物环合,  Cyclizing a compound of formula 4,
Figure imgf000004_0002
式中, 1 3和} 4分别代表 crc4垸基; (b)从反应混合物中分离出式 3化合物。
Figure imgf000004_0002
In the formula, 1 3 and} 4 respectively represent a c r c 4 fluorenyl group; (b) isolating the compound of formula 3 from the reaction mixture.
本发明方法使用垸氧基镁作为碱性环合可降低副反应的发生, 从而极大地提 高式 3化合物的收率, 进而降低式 3化合物的生产成本。 具体实施方式  In the method of the present invention, the use of magnesium alkoxide as the basic cyclization can reduce the occurrence of side reactions, thereby greatly improving the yield of the compound of formula 3, and further reducing the production cost of the compound of formula 3. detailed description
本发明提供了一种合成式 3化合物的方法, 它包括步骤: (a)以烷氧基镁作为碱 性环合剂, 在有机溶剂中使相应的式 4化合物环合, 形成式 3化合物, (b)然后分离 得到式 3化合物。  The present invention provides a method for synthesizing a compound of formula 3, which comprises the steps of: (a) using a magnesium alkoxide as a basic cyclizing agent, and cyclizing a corresponding compound of formula 4 in an organic solvent to form a compound of formula 3, ( b) The compound of formula 3 is then isolated.
在上述方法中, 式 3化合物的通式为:  In the above method, the general formula of the compound of formula 3 is:
Figure imgf000005_0001
Figure imgf000005_0001
3 其中, 选自 C 垸基。 较佳地, 选自甲基、 乙基、 丙基和丁基; 更佳地, ^为 甲基和乙基。 式 4化合物的通式为:
Figure imgf000005_0002
3 Among them, selected from C fluorenyl. Preferably, it is selected from the group consisting of methyl, ethyl, propyl and butyl; more preferably, ^ is methyl and ethyl. The compound of formula 4 has the general formula:
Figure imgf000005_0002
其中!^和 分别选自 C CJ 垸基。 较佳地, R3和!^分别选自甲基、 乙基、 丙基和 丁基; 更佳地, 和 分别为甲基和乙基。 among them! ^ And are selected from C CJ amidino, respectively. Preferably, R 3 and! ^ Are respectively selected from methyl, ethyl, propyl and butyl; more preferably, and are methyl and ethyl, respectively.
垸氧基镁可用式 5来表示:  Magnesium ethoxide can be expressed by Formula 5:
(R20)2Mg (R 2 0) 2 Mg
5 其中 R2选自 C6的垸基。 较佳地, R2选自甲基、 乙基、 丙基、 丁基、 戊基和 己基; 更佳地, R2选自甲基、 乙基、 丙基和丁基; 最佳地, R2为甲基、 乙基异丙 基和正丙基。 5 wherein R 2 is selected from a fluorenyl group of C 6 . Preferably, R 2 is selected from methyl, ethyl, propyl, butyl, pentyl and Hexyl; more preferably, R 2 is selected from methyl, ethyl, propyl and butyl; most preferably, R 2 is methyl, ethyl isopropyl and n-propyl.
所述垸氧基镁的制备可如下进行, 即通过单质金属镁与过量 Cr C6醇在高于室 温的温度下反应合成。 在本发明的一个较佳实例中, 所述温度优先为该醇的回流 温度。 所述醇可以是 -Ce的一元醇或含有(^-(:6的一元醇的溶剂; 较佳地, 所述 溶剂优选是单用( " C6的一元醇; 更佳地, 所述溶剂更优先是单用甲醇、 乙醇、 异 丙醇、 正丙醇。 The preparation of the magnesium alkoxide can be carried out by reacting and synthesizing elemental magnesium with excess C r C 6 alcohol at a temperature higher than room temperature. In a preferred embodiment of the present invention, the temperature is preferably the reflux temperature of the alcohol. The alcohol may be a monohydric alcohol or -Ce comprising (^ - (: Solvent 6 monohydric alcohol; preferably, the solvent is preferably alone ( "C 6 monohydric alcohol; and more preferably, the solvent is More preferred are methanol, ethanol, isopropanol, and n-propanol alone.
本发明的溶剂还可以是主要包含 (^一(:6的醇的混合溶液 (主要是指含量大于 70 % , 优选大于 80 % ) , 例如主要包含 ^一(:6醇的四氢呋喃混合溶液。 The solvent of the present invention may also be a mixed solution mainly containing (1% alcohol: 6 alcohol (mainly refers to a content greater than 70%, preferably greater than 80%), such as a tetrahydrofuran mixed solution mainly containing 1% alcohol ( 6 alcohol).
本发明的环合反应步骤(a)是在溶剂中进行的,所用的溶剂优选 的醇 (尤 其是一元醇)或其混合溶剂, 可选用 Cr (:6的一元醇或含有 Cr ( 6的一元醇的混合 溶剂, 尤其是单用 d- C6的一元醇作为溶剂, 更优先单用甲醇、 乙醇、 异丙醇、 正丙醇作为溶剂。 The cyclization reaction step (a) of the present invention is performed in a solvent. The solvent used is preferably an alcohol (especially a monohydric alcohol) or a mixed solvent thereof. C r (: 6 monohydric alcohol or C r ( 6 A mixed solvent of a monohydric alcohol, especially a monohydric alcohol of d-C 6 is used as a solvent, and methanol, ethanol, isopropanol, and n-propanol are more preferably used as a solvent.
环合反应的温度范围没有特别限制, 通常在 40Ό至选定溶剂的回流温度之间, 尤 其是 C6醇的回流温度可达 157°C。 较佳地, 反应温度的范围为 40-125°C, 更佳地为 55-120Ό , 最佳地为 60-10(TC。 常用溶剂的沸点如下 (常压):
Figure imgf000006_0001
在步骤 (b)中, 可用本领域常规的方法 (如 US 4, 180, 662 中所述的方法)分离式 3 化合物。 一种优选的分离方法是用二氯甲院 /2N HC1混合溶液萃取, 干燥浓缩后, 得 到式 3化合物的粗产物。 经有机溶液 (如甲醇)洗涤、 过滤、 烘干后可得到产物。 对于分离的产品, 可如下计算收率: 收率 = (产品质量 X原料分子量) /(原料投料量 X产品分子量) X 100%
The temperature range of the cyclization reaction is not particularly limited, and is usually between 40 ° F and the reflux temperature of the selected solvent, especially the reflux temperature of the C 6 alcohol can reach 157 ° C. Preferably, the reaction temperature ranges from 40 to 125 ° C, more preferably from 55 to 120 ° C, and most preferably from 60 to 10 ° C. The boiling points of common solvents are as follows (normal pressure):
Figure imgf000006_0001
In step (b), the compound of formula 3 can be isolated by methods conventional in the art (such as those described in US 4, 180, 662). A preferred separation method is extraction with dichloromethane / 2N HC1 mixed solution, and drying and concentration to obtain a crude product of the compound of formula 3. The product can be obtained after washing with organic solution (such as methanol), filtering, and drying. For separated products, the yield can be calculated as follows: Yield = (product quality X raw material molecular weight) / (raw material input amount X product molecular weight) X 100%
下面结合实施例详细说明本发明, 这些实施例只是用于说明目的, 并没有限制本 发明的范围。 实施例 1 The following describes the present invention in detail with reference to the examples. These examples are for illustrative purposes only and do not limit the scope of the present invention. Example 1
制备 6-氯- 4-羟基 -2-甲基- 2H-噻吩并(2, 3-e) - 1, 2-噻嗪 -1, 1-二氧化物 -3- 羧酸甲酯  Preparation of 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1,2-thiazine-1, 1-dioxide-3-carboxylic acid methyl ester
2升三口烧瓶中投入 1500ml 甲醇、 粉末状金属镁 19. 2g, 搅拌分散后加热回 流反应 3小时, 制得灰色的甲醇镁的甲醇溶液。  1500 ml of methanol and 19.2 g of powdered metallic magnesium were put into a two-liter three-necked flask, and the mixture was stirred and dispersed and heated under reflux for 3 hours to prepare a gray magnesium methoxide methanol solution.
然后,一次性投入 5-氯 -3- (N-甲氧羰基亚甲基 -N-甲基) -氨基磺酰噻吩 -2-羧 酸甲酯(按 US 4, 180, 662合成) 160g, 升温至 65°C反应, 以 HPLC (Alltiraa C18 5u Length 150mm)检测至产物含量不再上升为反应终点(大约 12小时)。  Then, 160 g of 5-chloro-3- (N-methoxycarbonylmethylene-N-methyl) -sulfamoylthiophene-2-carboxylic acid methyl ester (synthesized according to US 4, 180, 662) was added at once, The temperature was raised to 65 ° C and the reaction was detected by HPLC (Alltiraa C18 5u Length 150mm) as the end point of the reaction (about 12 hours).
反应毕, 冷却后倒入 1500ml 2N HC1与 800ml CH2C12组成的混合液中, 分层, 取有机相。 以 2 X 100ml CH2C12萃取水相, 合并有机相后, 用无水 Na2S04干燥。 过 滤,浓縮后所得固体以甲醇浸泡,过滤后烘干得浅黄色结晶固体 112g,收率 77. 2%, 熔点 200°C-202°C, 与标题化合物的熔点值相符。 实施例 2 After the reaction is completed, after cooling, it is poured into a mixed solution consisting of 1500 ml of 2N HC1 and 800 ml of CH 2 C1 2 , the layers are separated, and the organic phase is taken. The aqueous phase was extracted with 2 × 100 ml of CH 2 C1 2. The organic phases were combined and dried over anhydrous Na 2 S 0 4 . After filtration, the solid obtained after concentration was immersed in methanol, and dried after filtration to obtain 112 g of pale yellow crystalline solid with a yield of 77.2% and a melting point of 200 ° C-202 ° C, which was consistent with the melting point of the title compound. Example 2
制备 6-氯 -4-羟基 -2-甲基- 2H-噻吩并(2, 3-e) -l, 2-噻嗪- 1, 1-二氧化物 -3- 羧酸甲酯  Preparation of 6-chloro-4-hydroxy-2-methyl-2H-thieno (2,3-e) -1,2-thiazine-1,1-dioxide-3-carboxylic acid methyl ester
2升三口烧瓶中投入 1600ml乙醇、 粉末状金属镁 19. 2g, 碘甲垸 0. 5ml, 搅拌 分散后回流反应 3小时, 制得灰色的含乙醇镁的乙醇溶液。  In a two-liter three-necked flask, 1600 ml of ethanol and 19.2 g of powdered metal magnesium were added, and 0.5 ml of iodoformamidine was stirred and dispersed for 3 hours under reflux to prepare a gray ethanol solution containing magnesium ethoxide.
然后一次性投入 5-氯- 3- (N-甲氧羰基亚甲基 -N-甲基) -氨基磺酰噻吩 -2-羧酸 甲酯 160g, 升温至 80°C反应, 以 HPLC检测至产物含量不再上升为反应终点。  Then, 160 g of 5-chloro-3- (N-methoxycarbonylmethylene-N-methyl) -aminosulfonylthiophene-2-carboxylic acid methyl ester was put in one portion, and the temperature was raised to 80 ° C, and the reaction was detected by HPLC. Product content no longer rises to the end of the reaction.
反应毕, 冷却后倒入 2000ral 2N HC1与 800ral CH2C12组成的混合液中, 取有 机相。 以 2 X 100mlCH2Cl2萃取水相, 合并有机相。 有机相用无水 Na2S04干燥。 浓 缩千有机相后所得固体以甲醇浸泡, 烘干得浅黄色结晶固体 84g, 收率 58%, 熔点 200°C— 202°C。 实施例 3 After the reaction, after cooling, it was poured into a mixed solution consisting of 2000ral 2N HC1 and 800ral CH 2 C1 2 and the organic phase was taken. The aqueous phase was extracted with 2 × 100 ml CH 2 Cl 2 and the organic phases were combined. The organic phase was dried over anhydrous Na 2 S 0 4 . The solid obtained after concentrating the thousand organic phases was immersed in methanol, and dried to obtain 84 g of a pale yellow crystalline solid with a yield of 58% and a melting point of 200 ° C-202 ° C. Example 3
制备 6-氯- 4-羟基 -2-甲基 -2H-噻吩并(2, 3- e) - 1, 2-噻嗪- 1 , 1-二氧化物- 3- 羧酸甲酯 Preparation of 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1,2-thiazine-1, 1-dioxide-3 Methyl carboxylate
2升三口烧瓶中投入 1600ml异丙醇、 粉末状金属镁 19. 2g, 碘甲垸 1. 5ml, 搅 拌分散后回流反应 3小时, 制得灰色的含异丙醇镁的异丙醇溶液。  In a 2-liter three-necked flask, 1600 ml of isopropanol and 19.2 g of powdered metal magnesium, and 1.5 ml of iodoformamidine were stirred and dispersed for 3 hours under reflux to prepare a gray isopropanol solution containing magnesium isopropoxide.
然后一次性投入 5-氯 -3- (N-甲氧羰基亚甲基 -N-甲基)-氨基磺酰噻吩 -2-羧酸 甲酯 160g, 升温至 95°C左右反应, 以 HPLC检测至产物含量不再上升为反应终点。  Then, add 160 g of 5-chloro-3- (N-methoxycarbonylmethylene-N-methyl) -sulfamoylthiophene-2-carboxylic acid methyl ester at one time, and raise the temperature to about 95 ° C to react, and detect by HPLC Until the product content no longer rises as the end of the reaction.
反应毕, 冷却后倒入 2000ml 2N HC1与 800ml CH2C12组成的混合液中, 取有 机相。 以 2 X 100mlCH2Cl2萃取水相, 合并有机相。 有机相用无水 Na2S04干燥。 浓 缩干有机相后所得固体以甲醇结晶, 烘干得浅黄色结晶固体 60. 9g, 收率 42%, 熔 点 200°C - 202°C。 如前述, 现有技术中化合物 1的摩尔收率只有 24%, 而本发明中化合物 1的摩尔 收率最高可达 77. 2%, 相比现有技术提高了 3倍以上, 从而极大地降低了生产成本, 具有非常大的应用前景。 After the reaction, after cooling, it was poured into a mixed solution consisting of 2000 ml of 2N HC1 and 800 ml of CH 2 C1 2 , and the organic phase was taken. The aqueous phase was extracted with 2 × 100 ml CH 2 Cl 2 and the organic phases were combined. The organic phase was dried over anhydrous Na 2 S 0 4 . After the organic phase was concentrated to dryness, the obtained solid was crystallized from methanol, and dried to obtain a light yellow crystalline solid 60.9 g, a yield of 42%, and a melting point of 200 ° C-202 ° C. As mentioned above, the molar yield of Compound 1 in the prior art is only 24%, while the molar yield of Compound 1 in the present invention can reach up to 77.2%, which is more than 3 times higher than the prior art, thereby greatly reducing The production cost has a very large application prospect.
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独 引用作为参考那样。 此外应理解, 在阅读了本发明的上述讲授内容之后, 本领域技术 人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书 所限定的范围。 All documents mentioned in the present invention are incorporated by reference in this application, as if each document was individually incorporated by reference. In addition, it should be understood that after reading the above-mentioned teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.

Claims

权 利 要 求 Rights request
1. 一种制备通式为式 3的 6-氯 -4-羟基- 2-甲基- 2H-噻吩并(2, 3-e) - 1, 2- 噻嗪 -1, 1-二氧化物- 3-羧酸酯的方法,
Figure imgf000009_0001
式中, ^是^-^的垸基;
1. Preparation of 6-chloro-4-hydroxy-2-methyl-2H-thieno (2, 3-e) -1,2-thiazine-1, 1-dioxide of formula 3 -3-carboxylic acid ester method,
Figure imgf000009_0001
In the formula, ^ is a fluorenyl group of ^-^;
其特征在于, 该方法包括步骤:  It is characterized in that the method includes steps:
(a)以式 5的垸氧基镁作为碱性环合剂,在有机溶剂和 40°C-157°C反应温度下,  (a) Using methoxy magnesium of formula 5 as a basic cyclizing agent, at an organic solvent and a reaction temperature of 40 ° C-157 ° C,
(R20)2Mg 式中, !^是^-^的烷基; (R 2 0) 2 Mg In the formula,! ^ Is an alkyl group of ^-^;
使式 4的化合物环合,
Figure imgf000009_0002
式中, 和 1 4分别代表 (^-( 4的烷基;
Cyclizing a compound of formula 4,
Figure imgf000009_0002
In the formula, and 14 respectively represent (^-( 4 alkyl groups;
(b)从反应混合物中分离出式 3化合物。  (b) isolating the compound of formula 3 from the reaction mixture.
2. 如权利要求 1所述的方法, 其特征在于, 所述 R,、 R3、 1 4分别选自甲基、 乙基、 丙基和丁基。 2. The method according to claim 1, wherein said R ,, R 3, 1 4 are independently selected from methyl, ethyl, propyl and butyl.
3. 如权利要求 2所述的方法, 其特征在于 所述 R,、 R3、 R4分别选自甲基 和乙基。 3. The method according to claim 2, wherein the R ,, R 3 , and R 4 are selected from methyl and ethyl, respectively.
4. 如权利要求 1所述的方法, 其特征在于, 所述 R2选自甲基、 乙基、 丙基、 丁基、 戊基和己基。 4. The method according to claim 1, wherein said R 2 is selected from methyl, ethyl, propyl, butyl, pentyl and hexyl.
5. 如权利要求 4所述的方法, 其特征在于, 所述 R2选自甲基、 乙基、 丙基 和丁基。 5. The method according to claim 4, wherein the R 2 is selected from the group consisting of methyl, ethyl, propyl and butyl.
6. 如权利要求 4所述的方法, 其特征在于, 所述 R2选自甲基、 乙基、 异丙 基和正丙基。 6. The method according to claim 4, wherein the R 2 is selected from the group consisting of methyl, ethyl, isopropyl and n-propyl.
7. 如权利要求 1所述的方法, 其特征在于, 所述反应温度为 40-125°C。  7. The method according to claim 1, wherein the reaction temperature is 40-125 ° C.
8. 如权利要求 1所述的方法, 其特征在于, 所述反应温度为 60-100°C。  8. The method according to claim 1, wherein the reaction temperature is 60-100 ° C.
9. 如权利要求 1所述的方法, 其特征在于, 所述有机溶剂是(^-(:6—元醇或 其混合溶剂。 9. The method according to claim 1, wherein the organic solvent is (^-(: 6 -alcohol or a mixed solvent thereof). 10.
10. 如权利要求 1所述的方法,其特征在于,所述有机溶剂的含水量小于 5%。  10. The method according to claim 1, wherein the organic solvent has a water content of less than 5%.
PCT/CN2004/000792 2003-08-01 2004-07-13 A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE WO2005016937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN 03142015 CN1266155C (en) 2003-08-01 2003-08-01 6-chloro-4-hydroxy-2-methyl-2H-thieno-(2,3-e)-1,2-thiazine-1,1-dioxide-3
CN03142015.X 2003-08-01

Publications (1)

Publication Number Publication Date
WO2005016937A1 true WO2005016937A1 (en) 2005-02-24

Family

ID=34155583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000792 WO2005016937A1 (en) 2003-08-01 2004-07-13 A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE

Country Status (2)

Country Link
CN (1) CN1266155C (en)
WO (1) WO2005016937A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009872A1 (en) 2012-07-09 2014-01-16 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
CN106632403A (en) * 2017-01-23 2017-05-10 牡丹江医学院 Pain-relieving anti-inflammatory drug for operations and preparation method of pain-relieving anti-inflammatory drug for operations

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020667B (en) * 2010-09-06 2013-02-27 刘雨林 Method for synthesizing 6-chloro-4-hydroxyl-2-methyl-2H-thieno(2.3.e)-1.2thiazide-1.1-dioxide-3-methyl formate
US8757213B2 (en) 2011-11-04 2014-06-24 Blue Gentian, Llc Commercial hose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180662A (en) * 1977-09-06 1979-12-25 Hoffmann-La Roche Inc. Thiazine derivatives
US4224445A (en) * 1974-08-26 1980-09-23 Hoffmann-La Roche Inc. Thienothiazine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224445A (en) * 1974-08-26 1980-09-23 Hoffmann-La Roche Inc. Thienothiazine derivatives
US4180662A (en) * 1977-09-06 1979-12-25 Hoffmann-La Roche Inc. Thiazine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAN W ET AL: "Synthesis of Lornoxicam", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 33, no. 8, August 2002 (2002-08-01), pages 365 - 366 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009872A1 (en) 2012-07-09 2014-01-16 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
CN106632403A (en) * 2017-01-23 2017-05-10 牡丹江医学院 Pain-relieving anti-inflammatory drug for operations and preparation method of pain-relieving anti-inflammatory drug for operations
CN106632403B (en) * 2017-01-23 2018-09-11 牡丹江医学院 A kind of operation analgesic antiphlogistic medicine and preparation method thereof

Also Published As

Publication number Publication date
CN1266155C (en) 2006-07-26
CN1580059A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
CN1330644C (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
CN101993407B (en) Indoline compound for preparing silodosin and preparation method thereof
KR20080013920A (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide
CN111630049B (en) Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof
JP2004500324A (en) Novel synthesis and crystallization of piperazine ring-containing compounds
WO2005016937A1 (en) A SYNTHETIC METHOD FOR 6-CHLORO-4-HYDROXY-2-METHYL-2H-THIENO (2,3-e)-1,2-THIAZINE1, 1-DIOXIDE-3-CARBOXYLATE
CN105820174B (en) A kind of preparation method of polysubstituted thiophene diindyl derivative
TWI724031B (en) Process for preparing 1-(4-methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1h-pyrrolo [2,3-b]pyridin-3-yl-acetic acid
CN112645887A (en) Preparation method of quinazolinone derivative
RU2276148C2 (en) Method for preparing phthalanes
CN110256451B (en) Synthetic method of benzofuro [2,3-b ] quinoline derivative
CN112094219B (en) Method for preparing intermediate of potassium ion competitive retarder
RU2709493C1 (en) Method of producing roxadustat
CN104703967A (en) Method for purifying fluvoxamine free base and method for preparing highly pure fluvoxamine maleate using same
CN1164585C (en) Xanthiphenyl ketamine or its salt and its preparing process
CN112125889A (en) Preparation method of 7-bromo-2- (1-methyl-1H-pyrazol-4-yl) quinoxaline
JP5463051B2 (en) Method for producing 1,4-dihydropyridine derivative
CN115028582B (en) Preparation method of N-aryl pyrazole medicine E-52862 and product thereof
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
CN105461634A (en) Preparation method of enzalutamide
CN110078604B (en) Preparation method of indeno-indanone derivative
US7446227B2 (en) Process for preparation of 5H-dibenzo[a,d] cycloheptene derivatives
CN1026586C (en) Thiazolidone derivatives, pharmaceutical compositions containing them and process for preparing same
JP2009096744A (en) Mannich reaction by using cyclic aminoether
CN116606250A (en) Preparation method of key intermediate of montelukast sodium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 806/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase